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Soluble epoxide hydrolase (sEH), a key enzyme in the metabolism of vasodilatory
epoxyeicosatrienoic acids (EETs), is sexually dimorphic, suppressed by estrogen, and
contributes to underlying sex differences in cerebral blood flow and injury after cerebral
ischemia. We tested the hypothesis that sEH inhibition or gene deletion in reproductively
senescent (RS) female mice would increase cerebral perfusion and decrease infarct size
following stroke. RS (15–18 month old) and young (3–4 month old) female sEH knockout
(sEHKO) mice and wild type (WT) mice were subjected to 45min middle cerebral artery
occlusion (MCAO) with laser Doppler perfusion monitoring. WT mice were treated with
vehicle or a sEH inhibitor t-AUCB at the time of reperfusion and every 24 h thereafter for
3 days. Differences in regional cerebral blood flow were measured in vivo using optical
microangiography (OMAG). Infarct size was measured 3 days after reperfusion. Infarct
size and cerebral perfusion 24 h after MCAO were not altered by age. Both sEH gene
deletion and sEH inhibition increased cortical perfusion 24 h after MCAO. Neither sEH
gene deletion nor sEH inhibition reduced infarct size in young mice. However, sEH gene
deletion, but not sEH inhibition of the hydrolase domain of the enzyme, decreased infarct
size in RS mice. Results of these studies show that sEH gene deletion and sEH inhibition
enhance cortical perfusion following MCAO and sEH gene deletion reduces damage after
ischemia in RS female mice; however this neuroprotection in absent is young mice.
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INTRODUCTION
Stroke is recognized as a sexually dimorphic disease, with more
women being affected than men (Bushnell et al., 2014). This
increased prevalence in women is partially due the fact that
women live longer than men. However, women also tend to
have poorer outcomes following stroke than men (Reeves et al.,
2008). Accordingly, stroke is the 3rd leading cause of death for
women, but only the 5th leading cause of death for men (Bushnell
et al., 2014). This sex difference has been recognized as a clin-
ically significant issue, as evidenced by the recent publication
of the American Heart Association’s first ever guidelines for
stroke prevention specifically in women (Bushnell et al., 2014).
Cerebrovascular events and stroke-related deaths in women
increase sharply after menopause (Lisabeth and Bushnell, 2012).
Although rodent studies have repeatedly shown that estrogen
protects against damage following cerebral ischemia (Liu et al.,
2009b), clinical trials failed to show a benefit of hormone replace-
ment therapy in post-menopausal women (Yang et al., 2013). It
has been hypothesized that this failure was due to the timing of
the hormone replacement (Suzuki et al., 2007), an idea that is
supported by recent rodent studies (Liu et al., 2012).
To circumvent the issues related to administering exogenous
estrogen, it may be possible to inhibit downstream vascular
injury mechanisms that are selectively induced in reproductively
senescent (RS) females by loss of estrogen. One potential candi-
date gene that is regulated by estrogen is soluble epoxide hydrolase
(sEH), the enzyme responsible for the breakdown of vasopro-
tective epoxyeicosatrienoic acids (EETs) into inactive dihydrox-
yeicosatrienoic acids (DHETs). EETs can protect the brain from
ischemic injury by multiple mechanisms including vasodilation,
cytoprotection, and suppression of post-ischemic inflammation
(Iliff and Alkayed, 2009). Estradiol reduces both basal and post-
ischemic sEH expression in females, an effect which may be
neuroprotective (Koerner et al., 2008).
sEH has been shown to play a role in stroke risk and ischemic
outcome. In humans, sEH gene (EPHX2) polymorphisms have
been shown to alter stroke incidence (Gschwendtner et al., 2008;
Fava et al., 2010) and ischemic outcome (Koerner et al., 2007).
Further, sEH inhibition has been shown to reduce infarct size
in young male stroke-prone spontaneously hypertensive rats
(Dorrance et al., 2005; Simpkins et al., 2009) and young male
mice (Zhang et al., 2007, 2009; Jouihan et al., 2013). In addi-
tion, in young male mice sEH gene deletion also reduces infarct
size (Zhang et al., 2008). Conversely, these protective effects of
sEH gene deletion are not observed in young intact female mice
but are observed in ovariectomized female mice (Zhang et al.,
2009), suggesting that ovarian hormones may provide protection
by reducing sEH expression.
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Since estradiol levels decline with age (Barron and Pike, 2012;
Lisabeth and Bushnell, 2012), we hypothesized that sEH inhibi-
tion/gene deletion may be protective in RS female mice similar
to what we have observed in ovariectomized mice. We hypothe-
sized that loss of estrogen after RS would remove the inhibitory
effect of estrogen on sEH and increase its expression. We further
hypothesized that sEH inhibition or gene deletion in RS female
mice would increase cerebral perfusion and decrease infarct size
following stroke. Our data show that although neither estrogen
levels nor sEH expression changed with age in our mouse model,
sEH gene deletion enhances cerebral perfusion in RS females and
protects against ischemic damage.
MATERIALS AND METHODS
This study was conducted in accordance with the National
Institutes of Health guidelines for the care and use of animals
in research, and protocols were approved by the Institutional
Animal Care and Use Committee at Oregon Health and Science
University, Portland, OR, USA.
ANIMAL MODEL
Young (3–4 month old), middle aged (11–12 month old), and
RS (18–22 month old) female C57BL/6 (wild type; WT) mice
purchased from Charles River were used for sEH protein anal-
ysis studies. For stroke studies, WT mice were purchased as
C57BL/6 mice from Charles River and as C57BL/6J mice from
Jackson laboratories depending on the comparison group. For
aging studies not involving transgenic mice, the C56BL/6 mice
were used. For aging studies involving sEHKO mice, which are
on a C57BL/6J background, C56BL/6J mice were used. Age-
matched RS (15–18 month old) or young (3–4 month old) female
mice were used. The sEH inhibitor trans-4-[4-(3-Adamantan-1-
yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB) was developed
and generously provided by Dr. Bruce Hammock, University of
California, Davis, CA (Liu et al., 2009a). Vehicle (4% PEG400 in
water) or t-AUCB (1mg/kg) were administered i.p. at the time
of reperfusion and every 24 h thereafter for 3 days. Homozygous
sEHKO mice were generated from an in-house breeding colony.
Genotype was confirmed by PCR, as previously described (Sinal
et al., 2000).
TRANSIENT MIDDLE CEREBRAL ARTERY OCCLUSION
Transient focal ischemia was achieved by occluding the mid-
dle cerebral artery for 45min as previously described (Zhang
et al., 2009). Briefly, mice were anesthetized with isoflurane and
kept warm with water pads. Body temperature was maintained
at 37 ± 0.5◦C. A small laser-Doppler probe was affixed to the
skull to monitor cortical perfusion and verify vascular occlu-
sion and reperfusion. Unilateral middle cerebral artery occlusion
(MCAO) was achieved by advancing a 6-0 nylon monofilament
suture into the right internal carotid artery via the external carotid
artery stump until the laser-Doppler signal dropped to <20% of
baseline.
OPTICAL MICROANGIOGRAPHY
OMAG was performed 24 h prior to ischemia and again 24 h after
MCAO as previously described (Iliff et al., 2009; Zhang et al.,
2009). Blood perfusion was visualized and quantified based on
endogenous light scattering from moving blood cells within the
brain. We used a superluminescent diode with a central wave-
length of 1, 310 nm and a full-width, half-maximum bandwidth
of 50 nm to illuminate the OMAG system. The spectral interfero-
grams formed by the reference light and the light backscattered
from the tissue sample were detected by a custom-built, high-
resolution and high-speed spectrometer. A final volume data cube
of 1000 × 500 × 512 (x − y − z) voxels was built from which the
three-dimensional OMAG structural and flow images were com-
puted. The three-dimensional scan represented a physical volume
with the following x − y − z dimensions: 2.5 × 2.5 × 2.0mm3.
MEASUREMENT OF INFARCT SIZE
Infarct size was measured by 2,3,5-triphenyltetrazolium chlo-
ride (TTC) stain 72 h after reperfusion, as previously described
(Zhang et al., 2009). To estimate infarct size, olfactory bulbs
and cerebellum were removed and the brain was sectioned
into four equally spaced 2-mm coronal sections (between +3
and −5mm relative to bregma). TTC stained brain sections were
photographed, and infarcted (unstained) areas were measured
with MCID (InterFocus Imaging Ltd, Linton, Cambridge, UK)
imaging software. To account for the effect of edema, we esti-
mated infarct size indirectly by subtracting the uninfarcted area in
the ipsilateral hemisphere from the total area of the contralateral
hemisphere.
HORMONE ASSAYS
Serum 17-beta estradiol (E2) levels and testosterone (T) levels
were measured at the Endocrine Technology Support Core Lab
at the Oregon National Primate Research Center at OHSU.
Extraction-radioimmunoassay (Ext-RIA) with liquid chro-
matographic separation of different steroids before the Ext-RIA
was used (Rasmussen et al., 1984). This technique is sample
volume-independent; where higher steroid levels in the sample
can be detected with less volume. Briefly, mouse serum or
plasma samples (20 to 200µl) were brought to 300µl with 0.1%
bacto-gelatin in phosphate buffered saline (PBS) and then 5ml
redistilled diethyl ether was added to each sample. After shaking
for 3min, samples were centrifuged and then frozen in a dry
ice-ethanol bath. The ether-soluble fraction was decanted from
the frozen aqueous fraction into a collecting tube, and dried
under forced air. The extract was then re-dissolved in 200µl
of column solvent (Hexane:benzene:methanol = 62:20:13) and
added to a 1 × 6 cm all-glass column containing 1 g Sephadex
LH-20 for separation of steroids. Each fraction was dried under
forced air stream and subjected to its respective RIA, i.e., an
ultrasensitive E2 RIA with sensitivity at 1 pg/tube or a T RIA with
sensitivity at 3 pg/tube. Hormonal values, expressed as pg/ml for
E2 or ng/ml for T, were corrected for extraction-chromatography
losses determined by radioactive trace recovery performed
simultaneously with sample extraction; hot recovery is usually
between 60 and 80%. The overall inter-assay variation for
steroid extraction radioimmunoassays was less than 15% and the
intra-assay variations did not exceed 10%.
WESTERN BLOT
Mice were perfused with ice-cold heparinized saline to remove
blood from brains prior to tissue collection. Brains were
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homogenized in lysis buffer containing sucrose (250mM), potas-
sium chloride (60mM), tris-hydrochloride (15mM), sodium
chloride (15mM), ethylenediaminetetraacetate (EDTA, 5mM),
ethylene glycol tetraacetic acid (EGTA, 1mM), phenylmethane-
sulfonylfluoride (PMSF, 0.5mM), dithiothreitol (DTT, 10mM),
1 Complete Mini-EDTA free Protease Inhibitor Cocktail tablet
(Roche Diagnostics, Indianapolis, IN), and 10µl/ml each of
phosphatase inhibitor solution 1 and phosphatase inhibitor
solution 2 (Sigma-Aldrich, St. Louis, MO). Lysates were then
centrifuged at 2000 × g for 10min at 4◦C, supernatant col-
lected and centrifuged at 17,000 × g for 20min at 4◦C,
and the remaining supernatant was collected. Protein samples
(40µg) were separated by gel electrophoresis and then trans-
ferred to Polyvinylidene Difluoride (PVDF) membranes. Blots
were blocked in 5% dry milk, and incubated at 4◦C overnight
with a primary rabbit polyclonal antibody against murine sEH
(1:500; Cayman Chemical, Ann Arbor, MI) or beta actin (1:2000;
Sigma-Aldrich). The signal was visualized using a horseradish
peroxidase-linked (HRP) secondary antibodies against rabbit
(1:1000; GE Healthcare, Salt Lake City, UT), or mouse (1:1000;
GE Healthcare) followed by detection using Supersignal chemilu-
minescent reagents (Thermo Fisher Scientific) with a FluorChem
FC2 (Protein Simple, Santa Clara, CA). Blots were stripped using
Restore Western Blot Stripping Buffer (Thermo Fisher Scientific)
and re-blocked in milk after imaging each blot for sEH and prior
to incubation in a subsequent primary antibody for beta actin.
Densitometry was quantified with AlphaView software (Protein
Simple). Data were normalized to the loading control beta actin,
then they were expressed relative to levels in young females.
STATISTICAL ANALYSIS
Data were analyzed using two-way analysis of variance with post-
hoc Newman–Keuls test for multiple comparisons. The criterion
for statistical significance was set at P < 0.05. All values are
reported as mean ± standard error.
RESULTS
sEH EXPRESSION DID NOT CHANGE WITH AGE
In order to determine if sEH expression in brain tissue changes
with age, brains were collected from young (3–4 months old),
middle age (11–12 months), and RS (18–22 months old) WT
female mice. sEH protein expression in brain, measured via
western blot, did not vary with age in female mice (Figure 1).
PERFUSION DURING MCAO IS NOT ALTERED BY sEH INHIBITION/GENE
DELETION OR AGE
Young (3–4 months old) and RS (15–18 months old) WT and
sEHKO mice were subjected to a 45min MCAO followed by
reperfusion. A separate cohort of WTmice received vehicle or the
sEH inhibitor t-AUCB (1mg/kg, i.p.) at the time of reperfusion
and every 24 h thereafter for 3 days. Characteristics of study mice
including age and body weight are presented in Table 1. Body
weight increased with age for all treatment groups. In addition,
RS sEHKO mice had elevated body weight compared to WT RS
mice. Relative perfusion of the MCA territory was measured by
laser Doppler probe continuously at baseline, during the occlu-
sion, and during 5min post-reperfusion (averages of 5–15min
FIGURE 1 | sEH expression did not change with age. sEH expression
was measured via Western blot in brains collected from young (3–4 months
old), middle age (11–12 months old), and reproductively senescent (RS;
18–22 months old) female wild type mice. sEH expression was normalized
to beta actin expression and is shown as a ratio relative to expression in
young female mice. No significant differences were observed between age
groups. N = 7–8 per group.
Table 1 | Characteristics of MCAO Study Mice.
Age (months) Body weight (g)
WT young 3–4 19.6± 0.4
sEHKO young 3–4 20.4± 0.3
WT RS 17–18 25.5± 0.5*
sEHKO RS 15 29.2± 1.0*#
Veh young 3–4 21± 0.4
t-AUCB young 3–4 20.9± 0.3
Veh RS 17–18 29.4± 0.7*
t-AUCB RS 17–18 29.2± 1.1*
Age range and average body weight, during MCAO are shown for each experi-
mental group. WT, wild type; sEHKO, soluble epoxide hydrolase knockout; RS,
reproductively senescent.
*p < 0.05 vs. young mice of same treatment group.
#p < 0.05 compared to WT RS mice.
intervals are shown). Relative perfusion during occlusion and
reperfusion was not altered by age, sEH gene deletion, or sEH
inhibition (Figure 2).
sEH INHIBITION/GENE DELETION INCREASES CORTICAL PERFUSION
24 H AFTER MCAO
We have previously shown that cortical perfusion is higher in
young females compared to young males after MCAO and that
this effect is mediated by sEH in male mice (Zhang et al., 2009).
We sought to determine if sEH also played a role in post-ischemic
cortical perfusion in aged female mice. 24 h after MCAO, cortical
perfusion was measured via optical microangiography (OMAG)
in young and RS WT and sEHKO mice and WT mice treated
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FIGURE 2 | Perfusion during MCAO is not altered by sEH
inhibition/gene deletion or age. Relative perfusion, measured by laser
Doppler probe, of the MCA territory measured continuously (averages of
5–15min intervals are shown) at baseline, during the occlusion, and during
5min post-reperfusion in young and reproductively senescent (RS) WT and
sEHKO mice (A) and WT mice treated with vehicle or the sEH inhibitor
t-AUCB (B). (A) Perfusion during occlusion and reperfusion was not altered
by age or sEH gene deletion. (B) Perfusion during occlusion and reperfusion
was not altered by age or sEH inhibition. N = 9–15 per group.
with vehicle or the sEH inhibitor t-AUCB at the time of reper-
fusion and then treated again 24 h later. Cortical perfusion was
not altered by age. However, cortical perfusion was increased in
sEHKO mice compared to WT mice [Figure 3A, F(1, 37) = 9.38,
p < 0.01]. Cortical perfusion was also enhanced in WT mice that
received treatment with the sEH inhibitor compared to vehicle
treated WT mice [Figure 3B, F(1, 36) = 6.86, p < 0.05].
sEH GENE DELETION REDUCES INFARCT SIZE 72 H AFTER MCAO IN RS
FEMALE MICE
We have previously shown that in young intact female mice
sEH gene deletion does not alter infarct size after MCAO, while
in ovariectomized female mice sEH gene deletion did decrease
infarct size (Zhang et al., 2009). However, the effects of sEH gene
deletion/inhibition in aged females are unknown. We compared
infarct size 72 h after MCAO in young and RS female WT and
sEHKO mice. A main effect of genotype was detected [F(3, 114) =
9.99, p < 0.0001]. Post-hoc test revealed, as previously observed,
that sEH gene deletion had no effect on infarct size in young intact
mice (Figures 4A,B). In addition, infarct size was not altered by
age in WT mice. However, RS sEHKO mice had significantly
decreased infarct size in both the cortex and the total hemisphere
compared to RS WT mice and young WT mice (Figures 4A,B,
p < 0.05). Next, we determined if sEH inhibition, when admin-
istered after the ischemic event, could provide protection in aged
female mice. The sEH inhibitor t-AUCB (1mg/kg; i.p.) or vehicle
treatment was administered at the time of reperfusion and then
FIGURE 3 | sEH inhibition/gene deletion increases cortical perfusion
24h after MCAO. Cortical perfusion was measured via optical
microangiography (OMAG) in young and reproductively senescent (RS) WT
and sEHKO mice (A) and WT mice treated with vehicle or the sEH inhibitor
t-AUCB (B) 24h prior to MCAO and then again 24 h after MCAO. Perfusion
is shown as a percent change from the baseline scan. (A) Post-ischemic
cortical perfusion was not altered by age in WT mice. Post-ischemic cortical
perfusion was increased in sEHKO mice compared to WT mice of both age
groups (∗p < 0.01). (B) Post-ischemic cortical perfusion was not altered by
age in vehicle-treated WT mice. Post-ischemic cortical perfusion was
increased by sEH inhibition in WT mice (∗p < 0.05). N = 8–12 per group.
every 24 h thereafter for 3 days prior to infarct analysis. A main
effect of treatment was detected [F(3, 135) = 9.36, p < 0.0001].
Post-hoc tests revealed that, similar to sEH gene deletion, sEH
inhibition also did not provide protection in young female mice.
However, in RS mice sEH inhibition reduced infarct size in both
the cortex and the total hemisphere compared to youngmice with
vehicle treatment but not in comparison to RS mice treated with
vehicle (Figures 4C,D, p < 0.01).
EFFECTS OF sEH INHIBITION/GENE DELETION ON SERUM HORMONE
LEVELS 72 H AFTER MCAO
Since estradiol is known to provide protection from ischemic
damage in young female mice, if sEH inhibition or gene deletion
significantly altered estradiol levels this could potentially have
contributed to the observed differences in infarct size between
groups. Serum estradiol and testosterone levels were measured
72 h after MCAO in young and RS WT and sEHKO female mice
and in young and RS WT female mice treated with vehicle or the
sEH inhibitor t-AUCB. Estradiol levels were not altered by age or
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery January 2015 | Volume 5 | Article 290 | 4
Zuloaga et al. sEH, aging, and stroke
FIGURE 4 | sEH gene deletion reduces infarct size 72h after MCAO in
RS female mice. Three days after MCAO, infarct size was measured via
TTC stain in young and reproductively senescent (RS) WT and sEHKO
mice (A,B) and WT mice treated with vehicle or the sEH inhibitor t-AUCB
(C,D). (A) Representative infarct sizes in WT and sEHKO mice. (B) Infarct
size was not altered by age in WT mice or by sEH gene deletion in young
mice. In RS mice, infarct size was decreased in the cortex and total
hemisphere of sEHKO mice compared to WT mice (∗p < 0.05). (C)
Representative infarct sizes in vehicle and t-AUCB treated mice. (D)
Infarct size was not altered by age in vehicle-treated WT mice or by sEH
inhibition in young mice. In RS mice, sEH inhibition decreased infarct size
in both the cortex and total hemisphere compared to young
vehicle-treated mice, but not compared to RS vehicle-treated mice
(∗p < 0.05). N = 9–15 per group.
sEH gene deletion (Figure 5A). However, a main effect of geno-
type was found for testosterone levels [F(1, 38) = 5.68, p < 0.05],
with post-hoc test revealing significantly decreased testosterone in
RS but not young sEHKOmice compared toWTmice (Figure 5B,
p < 0.05). A main effect of t-AUCB treatment on estradiol lev-
els was detected [F(1, 46) = 13.13, p < 0.001], with post-hoc tests
revealing that estradiol levels were significantly decreased by
sEH inhibition compared to vehicle in both young and RS mice
(Figure 5C, p < 0.001). Testosterone levels were not altered by
sEH inhibition (Figure 5D).
DISCUSSION
The goal of the current study was to determine if sEH inhi-
bition or gene deletion could improve cerebral perfusion and
reduce ischemic damage in aged female mice. We found that
sEH gene deletion/inhibition enhances cortical blood flow in
both young and RS female mice following cerebral ischemia.
Additionally, in RS, but not young mice, sEH gene deletion also
reduced infarct size in both the cortex and total hemisphere.
These findings suggest that while sEH plays a role in cerebral
blood flow response to ischemia in both young and RS females,
it does not influence ischemic damage in young females, but
provides protection in RS females. Therefore, our current data
indicate that the role of sEH in ischemic damage in females is
age-dependent.
EETs are known to provide protection against ischemic dam-
age via a variety of neuroprotective mechanisms including:
enhanced vasodilation (Iliff et al., 2010), improving cerebrovas-
cular structure and microvascular density (Simpkins et al., 2009),
inhibition of platelet adhesion (Heizer et al., 1991), reduction of
inflammation (Spector and Norris, 2007), reduction of oxidative
stress (Yang et al., 2001), reduction of apoptosis, or activation
of protective signal transduction (Iliff et al., 2010; Merkel et al.,
2010).
In line with this, sEH gene polymorphisms in the human
sEH gene (EPHX2) have been shown to alter stroke incidence
(Gschwendtner et al., 2008; Fava et al., 2010) and ischemic out-
come (Koerner et al., 2007). Further, we have previously shown
that a human variant of the sEH gene that increases sEH enzy-
matic activity is associated with increased cell death in cortical
neurons exposed to oxygen-glucose deprivation and reoxygena-
tion, while a mutation that reduces sEH activity provides protec-
tion from neuronal cell death (Koerner et al., 2007). Inhibition of
sEH or sEH gene deletion has also been shown to be protective
in rodent models of cerebral ischemia. Specifically, sEH inhibi-
tion has been shown to reduce infarct size in young male rats
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FIGURE 5 | Effects of sEH inhibition/gene deletion on serum
hormone levels 72h after MCAO. Three days after MCAO, serum
estradiol (A,C) and testosterone (B,D) levels were measured in young
and reproductively senescent (RS) WT and sEHKO mice (A,B) and WT
mice treated with vehicle or the sEH inhibitor t-AUCB (C,D). (A)
Estradiol levels were not altered by age or sEH gene deletion. (B)
Testosterone levels were not altered by age or by sEH gene deletion in
young mice. In RS mice, sEHKO mice had decreased testosterone
levels compared to WT mice (∗p < 0.05). (C) Estradiol levels were
decreased by sEH inhibition in both young and RS mice (∗p < 0.05). (D)
Testosterone levels were not altered by age or sEH inhibition in WT
mice. N = 10–15 per group.
(Dorrance et al., 2005; Simpkins et al., 2009) and youngmalemice
when administered as a pre-treatment (Zhang et al., 2007, 2009;
Jouihan et al., 2013) or at the time of reperfusion (Zhang et al.,
2007). We have shown in young male mice that sEH gene dele-
tion also reduces infarct size (Zhang et al., 2008). sEH inhibition
has also been shown to reduce neurological deficits after MCAO
in male rats (Simpkins et al., 2009).
sEH appears to contribute to stroke risk and ischemic damage,
in part, via a vascular mechanism. We have shown that male sEH
knockout (sEHKO) mice have enhanced regional cerebral blood
flow during MCAO compared to WT male mice (Zhang et al.,
2008). The effects of EETs on ischemic injury also appear to be
sexually dimorphic. We have previously shown that cerebrovas-
cular expression and activity of sEH are lower in female than
male mice (Zhang et al., 2009). While sEH gene deletion reduces
infarct size in young male mice, these protective effects of sEH
gene deletion are not observed in young intact female mice but
are observed in ovariectomized female mice (Zhang et al., 2009).
This lack of protection is young intact females is likely due to the
fact that these mice already have very low sEH expression (Zhang
et al., 2009) because estrogen suppresses sEH expression (Koerner
et al., 2008). We have also shown that cerebral blood flow during
MCAO is higher in intact WT female mice compared with male
mice and ovariectomized female mice. Sex differences in cere-
bral blood flow during MCAO were absent in sEHKO mice, due
to increased blood flow in the male and ovariectomized female
mice (Zhang et al., 2009). This data suggests that ovarian hor-
mones may improve cerebral blood flow via decreases in sEH
since ovariectomy does not impair cerebral blood flow in sEHKO
mice (Zhang et al., 2009).
Our data show that both sEH gene deletion and sEH inhibition
increase post-ischemic cortical perfusion in both young and RS
female mice. We have previously shown that sEH gene deletion
drastically decreases cerebrovascular hydrolase activity in both
male and female mice (Zhang et al., 2009). Furthermore, we have
also shown that in vivo sEH inhibition with t-AUCB increases
EETs concentrations in mouse brain (Jouihan et al., 2013). Since
EETs are known to cause vasodilation (Iliff et al., 2010), enhanced
vasodilation could be responsible for the observed increase in cor-
tical perfusion. We have also previously shown that sEH gene
deletion increases cortical blood flow in young male mice dur-
ing ischemia but not in young female mice (Zhang et al., 2009).
In line this, in the current study we did not detect differences in
perfusion with sEH gene deletion or inhibition in female mice
in either age group during MCAO or immediately (5min) after
reperfusion. However, differences between groups emerged when
cortical perfusion was measured via OMAG 24 h after ischemia.
At the 24 h time point, both sEH inhibition and sEH gene dele-
tion increased perfusion in both age groups. Thus, the time course
of modulation of cerebral perfusion by sEH following ischemia
appears to be sexually dimorphic, emerging early in males, but
with delayed onset in females.
In RS female mice sEH gene deletion, but not sEH inhibition,
provided protection against ischemic damage. There was no effect
for t-AUCB in any age group, although there was a trend toward
a decrease in infarct size in tAUCB-treated compared to vehicle
RS mice. Taken together, the data in Figures 4A,B suggest that
sEH gene deletion, but not pharmacological inhibition, decreases
infarct size in RS females. Pharmacological inhibition seems,
however, to potentiate the age-related decrease in infarct size
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observed in C56BL/6 (Figure 4B). A possible explanation for the
discrepancy between the effects of sEH gene deletion compared to
pharmacological inhibition may be related to the recent discovery
that sEH is a bifunctional enzyme containing both phosphatase
and hydrolase enzymatic activities (Cronin et al., 2003; Newman
et al., 2003). While both of these enzyme activities are abol-
ished by gene deletion, only the hydrolase activity is inhibited
by the pharmacological blockers. The other explanation is that
life-long deletion of sEH in sEHKO mice may lead to compen-
satory changes; for example, vascular remodeling, which are not
observed following acute pharmacological inhibition (Koerner
et al., 2008).
In contrast to the protection observed in RS mice with sEH
gene deletion, no effect of was seen in young mice. Thus, the
effects of sEH gene deletion appear to be age-dependent in
females. The lack of protection in young female mice supports
our previous study in which we did not observe differences in
infarct size between young female WT and sEHKO mice (Zhang
et al., 2009). The lack of reduction infarct size in young mice
despite an increase in post-ischemic perfusion seems contradic-
tory. However, there are several potential explanations for this
finding. First, although blood flow does play a role in ischemic
outcome, there are many other factors that also contribute to
infarct size such as inflammation, oxidative stress, and hormonal
status. If sEH gene deletion/inhibition did not positively influ-
ence these other factors in the young mice, this would explain
why the improved blood flow did not lead to neuroprotection.
EETs are known to have anti-inflammatory (Spector and Norris,
2007), anti-oxidant (Yang et al., 2001), and anti-apoptotic effects
(Iliff et al., 2010; Merkel et al., 2010); therefore, it is possi-
ble that sEH gene deletion caused greater neuronal protection
through one of these mechanisms in the aged female mice com-
pared to the young female mice. Second, endogenous vascular
sEH expression may be lower in young mice than in RS mice.
We have previously observed that sEH expression is increased
in brains of aged female rats compared to young female rats
(unpublished observation). Although, we did not detect signifi-
cant differences in whole brain sEH expression with age in the
current study, there may have been differences in cerebrovascu-
lar sEH expression that were diluted by our use of the whole
brain instead of isolated vessels. Furthermore, since EETs levels
are regulated by both synthesis and degradation, it is possible
that although sEH protein expression was unchanged with age
EETs levels could have been higher in the young mice. If EETs
levels were already high in young mice but not in the RS mice,
then sEH inhibition/gene deletion would be expected to have
less of an effect in young compared to RS mice. A third possi-
ble explanation is that the lower testosterone levels observed with
sEH gene deletion in RS mice contributed to the reduction in
infarct size, since testosterone has been shown to increase infarct
size by increasing glutamate toxicity, inflammation, and apoptosis
(Hawk et al., 1998; Yang et al., 2002; Cheng et al., 2007). Reduced
estradiol levels observed with sEH inhibition in young mice may
have enhanced injury in young mice and masked any protec-
tive effects of sEH inhibition, since estradiol is known to protect
against ischemic injury through mechanisms including reduc-
ing inflammation, oxidative stress, and enhancing neurogenesis
and cerebral blood flow in young mice (Alkayed et al., 1998;
McCullough et al., 2001; Wen et al., 2004; Liu et al., 2009b; Li
et al., 2011). Conversely, reduced estradiol levels may not enhance
injury in RS mice, since the protective effects of estradiol appear
to decrease with age (Selvamani and Sohrabji, 2010; Liu et al.,
2012).
Few studies have compared stroke outcome in young and
RS female rodents. We did not observe an age-related change
in ischemic sensitivity. Our results are in line with previous
reports that showed no differences in infarct size between young
and RS females (Dubal and Wise, 2001; Manwani et al., 2013).
However, other studies have shown that aged female mice tend
to have larger infarct size than young female mice (Selvamani
and Sohrabji, 2010; Selvamani et al., 2014). Many of these stud-
ies have been conducted in middle aged mice (9–12 months old)
that are younger than the 15–18 months old female mice used
in the current study. Estradiol levels are known to decrease with
age (Barron and Pike, 2012; Lisabeth and Bushnell, 2012). We did
not detect an age-related decline in estradiol levels in the cur-
rent study. It has been reported that the transition to reproductive
senescence is associated with loss of cyclicity, rather than decrease
in peak hormone levels (Wise et al., 1994). Loss of cyclicity could
not have been detected in our studies, which used a single ter-
minal measurement of hormones. Furthermore, at the time of
blood collection, the young female mice displayed hormone levels
consistent with diestrus, the phase of their estrus cycles in which
estradiol levels are lowest (Walmer et al., 1992), or RS. It has been
demonstrated that stress increases the time spent in diestrus in
mice (Breen et al., 2012). In addition, it is well-documented that
stress decreases estradiol production in both humans and rodents
(Whirledge and Cidlowski, 2010). Therefore, when serum was
collected 72 h after the stroke surgery estradiol levels may have
been very low due to severe stress inhibiting the hypothalamic-
pituitary-gonadal axis. Since estradiol levels are already very low
in RS mice, we would not expect to see as much of a decrease in
estradiol levels in RS mice after stress. We also did not detect age-
related changes in testosterone levels. However, sEH inhibition,
but not gene deletion, did reduce estradiol levels in both young
and RSmice. Whether or not this reduction in estradiol level con-
tributed to infarct size is unknown. In addition, sEH gene deletion
also reduced testosterone levels in RS, but not young, mice. As
previously mentioned, since testosterone has been reported to
increase infarct size (Hawk et al., 1998; Yang et al., 2002; Cheng
et al., 2007), this reduction in testosterone levels could potentially
have contributed to the reduction in infarct size observed in RS
mice with sEH gene deletion.
In summary, we have shown that sEH gene deletion enhances
cortical blood flow and reduces infarct size in RS female mice fol-
lowing cerebral ischemia. Further, we have shown that although
sEH inhibition/gene deletion also increases cortical blood flow
in young female mice, this effect does not elicit neuroprotec-
tion. Therefore, our current data indicate that the role of sEH in
protecting against ischemic damage in females is age-dependent.
Understanding the downstream injury mechanisms elicited with
age in females could lead to new therapeutic strategies for stroke
to improve cerebral blood flow and reduce ischemic damage in
post-menopausal women.
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